Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Nov 29, 2017

Keywords

ClinConnect Summary

Background of the study:

Spondyloarthritis is the second most frequent form of chronic inflammatory arthritis with a prevalence of 0.5%. It effects mainly young adults and leads to major functional handicap due to inflammation of axial and peripheral joints as well as progressive ankylosis and structural damage.

In the late nineties Tumor Necrosis Factor (TNF) blockade was introduced as a successful treatment, but: only 50% responds well and tolerates, a-TNF does not halt the structural damage and TNF blockade does not induce long lasting remission as almost all patients relapse within a ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or non-pregnant/non-lactating females age 18-70
• • Diagnosis of SpA according to ESSG criteria and/or ASAS criteria
• • Active disease defined by ≥1 swollen and ≥ 1 tender joint, and at least 1 swollen knee or ankle joint at baseline
• Exclusion Criteria:
• • Evidence for infectious or malignant process (on chest X ray/MRI etc)
• • Patients taking opioid analgetics
• • Previous IL-17 therapy exposure
• • Previous use of cell-depleting therapies, biological immunomodulators (except for TNF blockade , as 25% may have been previously treated with 1 TNF blocking agent)
• • Significant medical problems or diseases